Charles River Laboratories International, Inc.
CRLNYSEHealthcare● Active
$181.34
$-4.45(-2.40%)
Market Cap$8.7B
P/E Ratio—
52W High$228.88
52W Low$140.78
Charles River Laboratories International, Inc. (CRL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CRL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$2.06
Est. $1.96 · +5.1%
Revenue
$1.00B
Est. $0.98B · +1.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 11-Quarter EPS Beat Streak
CRL reports quarterly as a NYSE-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $2.72 | — | — | — | $0.98B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $1.96 | $2.06 | +5.1% | $1.00B | $0.98B | +1.9% |
| ▲ Q1 FY2026 | Feb 18, 2026 | $2.33 | $2.39 | +2.6% | $0.99B | $0.99B | +0.7% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $2.32 | $2.43 | +4.7% | $1.00B | $0.99B | +1.8% |
| ▲ Q3 FY2025 | Aug 6, 2025 | $2.50 | $3.12 | +24.8% | $1.03B | $0.97B | +6.5% |
| ▲ Q2 FY2025 | May 7, 2025 | $2.06 | $2.34 | +13.6% | $0.98B | $0.96B | +2.6% |
| ▲ Q1 FY2025 | Feb 19, 2025 | $2.50 | $2.66 | +6.4% | $1.00B | $0.95B | +5.7% |
| ▲ Q4 FY2024 | Nov 6, 2024 | $2.42 | $2.59 | +7.0% | $1.01B | $0.98B | +3.5% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$2.72
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$2.06
EPS Est.
$1.96
EPS Surpr.
+5.1%
Revenue
$1.00B
Q1 FY2026
Feb 18, 2026Beat
EPS Actual
$2.39
EPS Est.
$2.33
EPS Surpr.
+2.6%
Revenue
$0.99B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$2.43
EPS Est.
$2.32
EPS Surpr.
+4.7%
Revenue
$1.00B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$3.12
EPS Est.
$2.50
EPS Surpr.
+24.8%
Revenue
$1.03B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$2.34
EPS Est.
$2.06
EPS Surpr.
+13.6%
Revenue
$0.98B
Q1 FY2025
Feb 19, 2025Beat
EPS Actual
$2.66
EPS Est.
$2.50
EPS Surpr.
+6.4%
Revenue
$1.00B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$2.59
EPS Est.
$2.42
EPS Surpr.
+7.0%
Revenue
$1.01B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $3.56 | $3.64 | $3.81 | 7 |
| Q3 FY2028 | $3.39 | $3.47 | $3.63 | 4 |
| Q2 FY2028 | $3.17 | $3.25 | $3.40 | 4 |
| Q1 FY2028 | $2.96 | $3.03 | $3.18 | 7 |
| Q4 FY2027 | $3.26 | $3.33 | $3.49 | 5 |
| Q3 FY2027 | $3.13 | $3.21 | $3.36 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.0B | $1.0B | $1.1B | 2 |
| Q3 FY2028 | $1.0B | $1.0B | $1.1B | 2 |
| Q2 FY2028 | $1.0B | $1.0B | $1.1B | 3 |
| Q1 FY2028 | $1.0B | $1.0B | $1.0B | 4 |
| Q4 FY2027 | $1.0B | $1.0B | $1.0B | 5 |
| Q3 FY2027 | $1.0B | $1.0B | $1.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +5.1% | $181.73 | $181.68 | -0.03% |
| ▲ Q1 FY2026 | Feb 18, 2026 | +2.6% | $158.53 | $158.00 | -0.33% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +4.7% | $177.85 | $167.70 | -5.71% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +24.8% | $167.49 | $150.33 | -10.25% |
| ▲ Q2 FY2025 | May 7, 2025 | +13.6% | $115.41 | $136.97 | +18.68% |
| ▲ Q1 FY2025 | Feb 19, 2025 | +6.4% | $154.39 | $165.00 | +6.87% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +7.0% | $188.68 | $214.20 | +13.53% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +17.1% | $228.80 | $199.96 | -12.60% |
Q2 FY2026-0.03%
Report Date
May 7, 2026
EPS Beat/Miss
+5.1%
Price Before
$181.73
Price After
$181.68
Q1 FY2026-0.33%
Report Date
Feb 18, 2026
EPS Beat/Miss
+2.6%
Price Before
$158.53
Price After
$158.00
Q4 FY2025-5.71%
Report Date
Nov 5, 2025
EPS Beat/Miss
+4.7%
Price Before
$177.85
Price After
$167.70
Q3 FY2025-10.25%
Report Date
Aug 6, 2025
EPS Beat/Miss
+24.8%
Price Before
$167.49
Price After
$150.33
Q2 FY2025+18.68%
Report Date
May 7, 2025
EPS Beat/Miss
+13.6%
Price Before
$115.41
Price After
$136.97
Q1 FY2025+6.87%
Report Date
Feb 19, 2025
EPS Beat/Miss
+6.4%
Price Before
$154.39
Price After
$165.00
Q4 FY2024+13.53%
Report Date
Nov 6, 2024
EPS Beat/Miss
+7.0%
Price Before
$188.68
Price After
$214.20
Q3 FY2024-12.60%
Report Date
Aug 7, 2024
EPS Beat/Miss
+17.1%
Price Before
$228.80
Price After
$199.96
Avg Beat Reaction+1.27%
Beat Rate8 / 8 quarters
Largest Move+18.68% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CRL ends December
Charles River Laboratories International, Inc. (CRL) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $2.06 — beating the analyst consensus of $1.96 by +5.1%. CRL has beaten EPS estimates for 11 consecutive quarters. The next CRL earnings date is expected around September 1, 2026.
Each quarter, investors track CRL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CRL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CRL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CRL earnings · 5 questionsCharles River Laboratories International, Inc.'s next earnings report is expected around September 1, 2026. CRL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CRL historically reports after market close (AMC).
CRL earnings datewhen is CRL earningsCRL next earnings datewhen does CRL report earningsCRL earnings calendar
▸ Source: FMP · Charles River Laboratories International, Inc. SEC filings · US GAAP · Charles River Laboratories International, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026